Dr. Lancet’s work on novel therapies in AML, including soon to be approved drugs such as CPX-351 and Vosaroxin, has been published extensively in high-level journals. He also has a special interest in the treatment of older adults with leukemia, and is the clinical leader and co-investigator on a large National Cancer Institute grant that focuses on treatment decision models for these patients. Dr. Lancet has received funding for his clinical trials through the National Cancer Institute and industry sponsors. In addition, Dr. Lancet was one of the original recipients of the prestigious National Cancer Institute Clinical Investigator Team Leadership Award.